[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1073606A1 - Use of edg receptor binding agents in cancer edg - Google Patents

Use of edg receptor binding agents in cancer edg

Info

Publication number
HK1073606A1
HK1073606A1 HK05106241.9A HK05106241A HK1073606A1 HK 1073606 A1 HK1073606 A1 HK 1073606A1 HK 05106241 A HK05106241 A HK 05106241A HK 1073606 A1 HK1073606 A1 HK 1073606A1
Authority
HK
Hong Kong
Prior art keywords
edg
cancer
receptor binding
binding agents
sphingosine
Prior art date
Application number
HK05106241.9A
Other languages
English (en)
Inventor
Thomas Baumruker
Volker Brinkmann
Montagne Kenneth Richard La
Peter T Lassota
Diana Mechtcheriakova
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1073606A1 publication Critical patent/HK1073606A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK05106241.9A 2002-05-16 2005-07-22 Use of edg receptor binding agents in cancer edg HK1073606A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24
PCT/EP2003/005125 WO2003097028A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer

Publications (1)

Publication Number Publication Date
HK1073606A1 true HK1073606A1 (en) 2005-10-14

Family

ID=29554311

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05106241.9A HK1073606A1 (en) 2002-05-16 2005-07-22 Use of edg receptor binding agents in cancer edg
HK09104529.3A HK1126127A1 (en) 2002-05-16 2009-05-18 Use of edg receptor binding agents in cancer edg

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09104529.3A HK1126127A1 (en) 2002-05-16 2009-05-18 Use of edg receptor binding agents in cancer edg

Country Status (23)

Country Link
US (2) US20090209495A1 (xx)
EP (3) EP1505959B1 (xx)
JP (3) JP5227492B2 (xx)
KR (1) KR20120125398A (xx)
CN (1) CN1652757B (xx)
AT (1) ATE412408T1 (xx)
AU (1) AU2003240655B2 (xx)
BR (1) BR0311173A (xx)
CA (1) CA2483594C (xx)
CY (1) CY1108719T1 (xx)
DE (1) DE60324416D1 (xx)
DK (1) DK1505959T3 (xx)
ES (1) ES2316758T3 (xx)
HK (2) HK1073606A1 (xx)
IL (3) IL164838A (xx)
MX (1) MXPA04011384A (xx)
NO (2) NO334074B1 (xx)
NZ (2) NZ560662A (xx)
PL (1) PL372103A1 (xx)
PT (1) PT1505959E (xx)
SI (1) SI1505959T1 (xx)
WO (1) WO2003097028A1 (xx)
ZA (1) ZA200408575B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
ES2327825T3 (es) 2002-01-11 2009-11-04 Daiichi Sankyo Company, Limited Derivado de aminoalcohol o derivado de acido fosfonico, y composicion medicinal que los contiene.
EP1511838A4 (en) 2002-06-07 2007-01-10 Es Cell Int Pte Ltd METHOD FOR CONTROLLING DIFFERENTIATION IN STEM CELLS
SI1602660T1 (sl) * 2003-02-18 2011-06-30 Kyorin Seiyaku Kk Derivati aminofosfonske kisline, njihove adicijske soli in modulatorji receptorja za S1P
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2557536C (en) 2004-02-24 2010-07-13 Sankyo Company Limited Amino alcohol compound
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP4993407B2 (ja) 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
KR20070058455A (ko) 2004-08-13 2007-06-08 프래시스 파마슈티컬즈 인코포레이티드 스핑고신-1-포스페이트(ｓ1ｐ) 수용체 활성을 조절하기위한 방법 및 조성물
WO2006078336A2 (en) * 2004-10-28 2006-07-27 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
WO2007089018A1 (ja) 2006-02-03 2007-08-09 Taisho Pharmaceutical Co., Ltd. トリアゾール誘導体
RU2395499C2 (ru) 2006-02-06 2010-07-27 Тайсо Фармасьютикал Ко., Лтд. Ингибитор связывания сфингозин-1-фосфата
CN101460197A (zh) * 2006-04-06 2009-06-17 诺瓦提斯公司 有机化合物的组合
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
CA2667706A1 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
PL2177512T3 (pl) 2007-08-01 2012-09-28 Taisho Pharmaceutical Co Ltd Inhibitor wiązania S1P1
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
RU2015111229A (ru) * 2008-11-11 2015-11-20 Новартис Аг Кристаллические формы гидрохлорида финголимода
US8680146B2 (en) * 2008-11-11 2014-03-25 Novartis Ag Organic compounds
PE20120337A1 (es) 2008-12-22 2012-04-24 Novartis Ag Producto conteniendo formas de dosificacion oral de fingolimod
CA2981830A1 (en) 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2456752A2 (en) * 2009-07-24 2012-05-30 ratiopharm GmbH Process for producing fingolimod salts
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
RU2012117563A (ru) 2009-09-29 2013-11-10 Новартис Аг Режим дозирования модулятора рецептора s1p
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
AU2012204835B2 (en) 2011-01-07 2015-07-09 Novartis Ag Immunosuppressant formulations
UA113507C2 (xx) 2011-02-07 2017-02-10 Модулятори s1p
KR20140084041A (ko) 2011-10-21 2014-07-04 노파르티스 아게 S1p 수용체 조절제 또는 효능제에 대한 투여 요법
CA2859628C (en) * 2011-12-23 2020-02-18 Meiji Seika Pharma Co., Ltd. S1p receptor modulating agent
US9499485B2 (en) 2012-08-06 2016-11-22 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
EP2879674B1 (en) 2012-08-06 2017-11-22 Biogen MA Inc. Compounds that are s1p modulating agents and/or atx modulating agents
US9850206B2 (en) 2012-11-20 2017-12-26 Biogen Ma Inc. S1P and/or ATX modulating agents
WO2014081756A1 (en) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. S1p and/or atx modulating agents
JP6434425B2 (ja) 2013-01-29 2018-12-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤
US20160039825A1 (en) 2013-03-15 2016-02-11 Biogen Ma Inc. S1p and/or atx modulating agents
CN103417970A (zh) * 2013-08-15 2013-12-04 泰山医学院 雌激素上调内皮系统保护分子鞘氨醇1-磷酸的应用
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3443986A1 (en) 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (xx) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
WO1995016691A1 (en) 1993-12-17 1995-06-22 Sandoz Ltd. Rapamycin derivatives useful as immunosuppressants
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
KR100437582B1 (ko) 1995-07-06 2004-12-17 노파르티스 아게 피롤로피리미딘및그들의제조방법
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
IL155065A (en) 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
EP1070080A4 (en) * 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
ES2265929T3 (es) * 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
ES2241781T3 (es) * 2000-02-09 2005-11-01 Novartis Ag Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.
CA2415678A1 (en) 2000-07-13 2003-01-10 Sankyo Company Limited Amino alcohol derivatives
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US20020156023A1 (en) * 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
CN1620461A (zh) 2001-03-26 2005-05-25 诺瓦提斯公司 2－氨基－丙醇衍生物
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
KR100913269B1 (ko) * 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제

Also Published As

Publication number Publication date
JP5227492B2 (ja) 2013-07-03
JP2010100637A (ja) 2010-05-06
AU2003240655A1 (en) 2003-12-02
NZ560662A (en) 2009-09-25
HK1126127A1 (en) 2009-08-28
DE60324416D1 (de) 2008-12-11
JP2013136584A (ja) 2013-07-11
EP1955696A2 (en) 2008-08-13
NZ536513A (en) 2007-10-26
CA2483594C (en) 2011-02-15
SI1505959T1 (sl) 2009-04-30
PL372103A1 (en) 2005-07-11
US20140303257A1 (en) 2014-10-09
ZA200408575B (en) 2005-07-27
IL164838A (en) 2013-12-31
DK1505959T3 (da) 2009-02-23
EP1505959A1 (en) 2005-02-16
IL229559A0 (en) 2014-01-30
AU2003240655B2 (en) 2007-09-06
MXPA04011384A (es) 2005-02-14
CN1652757A (zh) 2005-08-10
EP1955696B1 (en) 2014-05-28
ES2316758T3 (es) 2009-04-16
PT1505959E (pt) 2009-02-05
EP1944026B1 (en) 2013-06-26
NO20045312L (no) 2004-12-03
EP1505959B1 (en) 2008-10-29
BR0311173A (pt) 2005-03-15
WO2003097028A1 (en) 2003-11-27
JP2005529921A (ja) 2005-10-06
IL229550A0 (en) 2014-01-30
EP1944026A2 (en) 2008-07-16
CN1652757B (zh) 2012-02-08
US20090209495A1 (en) 2009-08-20
IL164838A0 (en) 2005-12-18
NO20130106L (no) 2004-12-03
CA2483594A1 (en) 2003-11-27
CY1108719T1 (el) 2014-04-09
EP1955696A3 (en) 2011-05-25
ATE412408T1 (de) 2008-11-15
EP1944026A3 (en) 2011-06-01
KR20120125398A (ko) 2012-11-14
NO334074B1 (no) 2013-12-02

Similar Documents

Publication Publication Date Title
IL229550A0 (en) Use of substances that bind to the edg receptor in cancer
EP1487436A4 (en) POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
EP1226823A3 (en) Method of treating certain cancers using an estrogen agonist/antagonist
AU2001227966A1 (en) Methods for treating tumors
YU38102A (sh) Derivati arilamina i njihova primena kao antitelomerazno sredstvo
GB0025583D0 (en) Technique for treating wells
HUP0303261A3 (en) Carbamate compounds for use in preventing or treating bipolar disorder
AP2004003070A0 (en) The method of treating cancer.
EP1401377A4 (en) CANCER TREATMENT METHODS
SI1350521T1 (sl) Imunoterapevtske kombinacije za zdravljenje tumorjev
GB2348899B (en) Surface treatment for tungsten carbide insert
AU1700700A (en) Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
WO2004031775A3 (en) Method for treating or preventing metastasis of colorectal cancers
MXPA01011721A (es) Metodos para predecir y/o diagnosticar el riesgo de cancer gastrico.
GB2379444A9 (en) Assay for cancer of the prostate
AU2001247560A8 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
HK1023990A1 (en) Surface treating agent for metals containing polyoxyethylene alkylphenol ether derivatives
GB9905113D0 (en) Chisel and plane-iron renovating and honing guide
ZA200307471B (en) Carbamate compounds for use in preventing or treating bipolar disorder.
EP1309330A4 (en) PHOTOSNESIBILIZING SUBSTANCES WITH LIGAND TARGETING PROPERTIES FOR TUMOR THERAPY
HK1061392A1 (en) 5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150515